article Open AccessTop 1% cited

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

Journal of the American Academy of Dermatology · 2016 · Vol. 75(3) · pp. 494–503.e6

Amy S. Paller✉(Northwestern University)Wynnis L. Tom(Rady Children's Hospital-San Diego)Mark Lebwohl(Icahn School of Medicine at Mount Sinai)Robin L. BlumenthalMark Boguniewicz(University of Colorado Denver)Robert S. CallLawrence F. Eichenfield(University of California, San Diego)Douglass W. Forsha(Jordan Valley Dermatology)William C. ReesEric L. Simpson(Oregon Health & Science University)Mary SpellmanLinda Stein Gold(Henry Ford Health System)Andrea L. Zaenglein(Pennsylvania State University)Matilda H. HughesLee T. ZaneAdelaide A. Hebert(The University of Texas Health Science Center at Houston)

View via DOI Publisher page

Abstract

Crisaborole demonstrated a favorable safety profile and improvement in all measures of efficacy, including overall disease severity, pruritus, and other signs of AD.

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Asthma and respiratory diseasesMedicineAtopic dermatitisAdverse effectClinical endpointInternal medicineDermatologyRandomized controlled trial

MeSH terms

Administration, CutaneousAdolescentAdultAgedBoron CompoundsChildChild, PreschoolDermatitis, AtopicDermatologic AgentsDouble-Blind MethodFemaleHumansMaleMiddle AgedOintments

Citations

549

FWCI

66.04

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases